Sumitomo Pharma and Poxel AnnounceTopline Results from Post-MarketingClinical Study on TWYMEEG® for the Treatment of Type 2 Diabetes in Japan

August 7, 2024

Osaka, Japan & Lyon, France, aug 07, 2024 – Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing
Clinical Study on TWYMEEG® for the Treatment of Type 2 Diabetes in Japan

DOWNLOAD Poxel press release

Sumitomo Pharma and Poxel AnnounceTopline Results from Post-MarketingClinical Study on TWYMEEG® for the Treatment of Type 2 Diabetes in Japan

THERANEXUS AND EXELTIS (INSUD PHARMA) ANNOUNCE AN AGREEMENT LICENSE FOR THE MARKETING OF THERANEXUS TX01 IN THE TREATMENT OF TWO RARE NEUROLOGICAL DISEASES

Establishment of a renewable equity financing line of a maximum amount of €2 million to support the ramp-up of the Revin industrial site

Poxel Announces Agreement with OrbiMed to Monetize a portion of TWYMEEG Royalties for USD 50 million

Links